Comparing lithium and valproate in reducing suicide risk: A territory-wide retrospective cohort study with pairwise and network meta-analysis.
Cuiling Wei, Jessie Ching Yan Su, Paco Chun Yeung Wong et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the effectiveness of lithium versus valproate in reducing suicide risk among patients with bipolar disorder using a retrospective cohort design. The cohort included 1,379 lithium users and 5,556 valproate users, revealing no significant difference in suicide risk (weighted HR = 0.76, 95% CI: 0.54-1.08) between the two treatments. Both medications were associated with lower suicide risk compared to no treatment.
Key findings
- No significant difference in suicide risk between lithium and valproate users (weighted HR = 0.76, 95% CI: 0.54-1.08).
- Pairwise meta-analysis of eight observational studies showed no significant difference (pooled HR = 0.87, 95% CI: 0.69-1.09).
- Network meta-analysis indicated both lithium (network HR = 0.46, 95% CI: 0.33-0.64) and valproate (network HR = 0.63, 95% CI: 0.45-0.88) reduced suicide risk compared to no treatment.
Why it matters
Understanding the comparative effectiveness of lithium and valproate in suicide prevention is crucial for clinicians managing bipolar disorder. This study provides evidence that both medications are effective, allowing for informed treatment decisions based on individual patient needs.